• Portfolio
  • Latest Articles

PSYCHEDELICS MARKET

June 3rd

Bill passed: wide range of psychedelics could be made legal in the US

  Archived
CPH further derisks acquisition as Halucenex adds to its psychedelics supply

May 14th 2021

CPH further derisks acquisition as Halucenex adds to its psychedelics supply

Halucenex forms important partnership as psychedelics space heats

May 6th 2021

Halucenex forms important partnership as psychedelics space heats

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

April 30th 2021

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

Move to legalisation of psychedelics could benefit CPH in the US

April 19th 2021

Move to legalisation of psychedelics could benefit CPH in the US

Halucenex agreement to give CPH another leg up in psychedelics

March 31st 2021

Halucenex agreement to give CPH another leg up in psychedelics

CPH to list on the OTC as it expands North American footprint

March 23rd 2021

CPH to list on the OTC as it expands North American footprint

$15M grant for psychedelics studies as calls to combat mental health intensify

March 18th 2021

$15M grant for psychedelics studies as calls to combat mental health intensify

Creso Pharma set to be the first ASX listed entrant in new market

March 15th 2021

Creso Pharma set to be the first ASX listed entrant in new market

Connect with us

EXPLORE

  • Finfeed Portfolio
  • Latest Articles
  • How It Works
  • Archived Articles
  • About StocksDigital
  • News
  • PORTFOLIOS

  • Next Investors
  • Catalyst Hunter
  • Wise-Owl
  • STOCKS

    FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS
      CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY  
    The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).
    © 2021   |   AFSL (CAR No.433913)